Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMDWCM2)

Drug Name
Rilvegostomig Drug Info
Synonyms AZD2936
Indication
Disease Entry ICD 11 Status REF
Non-small-cell lung cancer 2C25 Phase 1/2 [1]
Cross-matching ID
TTD Drug ID
DMDWCM2

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Programmed cell death protein 1 (PD-1) TTNBFWK PDCD1_HUMAN Not Available [1]
V-set and immunoglobulin domain-containing protein 9 (TIGIT) TTWNL74 TIGIT_HUMAN Not Available [1]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Programmed cell death protein 1 (PD-1) DTT PDCD1 5.635 4.661 4.706 5.15
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Non-small-cell lung cancer
ICD Disease Classification 2C25
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Programmed cell death protein 1 (PD-1) DTT PDCD1 7.26E-01 -0.01 -0.03
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT04995523) Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC. U.S.National Institutes of Health.